NCI-SNMMI Workshop on Targeted Radionuclide Therapy

On behalf of the National Cancer Institute (NCI) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) we would like to thank those who participated in the joint workshop: NCI-SNMMI Workshop on Targeted Radionuclide Therapy held March 18–19, 2013 at the National Institute of Health (NIH) in Bethesda, Maryland.  The purpose of the workshop was to stimulate discussion on the current and potential applications of targeted radionuclide therapy for the treatment of hematologic and solid cancers. 

The 2-day workshop proved to be a huge success. Through a series of presentations, individuals representing different professional perspectives on TRT offered a look at the state of the art and current challenges. Both the NCI and SNMMI feel that targeted radionuclide therapy is important in patient care and may be underutilized in the medical community.

Through this workshop, we were able to begin understanding the strengths and weaknesses of targeted radionuclide therapy as perceived by the oncology, radiation therapy, imaging and basic science communities as well as potential areas of future research in this arena.  In this way, we hope to help address any pressing issues, including adequate and effective funding for research in this field.

The final draft of the proceedings from the workshop was published in the Journal of Nuclear Medicine, January 2014 issue.NCIWorkshop_Photo

The recordings have been processed and are available for your viewing. (See below.)








Recorded Presentations - NCI-SNMMI Workshop on Targeted Radionuclide Therapy held March 18–19, 2013.

Day 1 Presentations:

George Sgouros, PhD – Physics of Radionuclide Therapy

Michael Zalutsky, PhD – Radiochemistry of Radionuclide Therapy

Richard Wahl, MD – Existing Radionuclide Therapy in the Clinic and Potential New Therapies

Eric Jacobson, MD – Radionuclide Therapy in Lymphoma

David Quinn, MD, PhD – Radionuclide Therapy in Bone Disease  

Jorge Carrasquillo, MD – Radionuclide Therapy in Neuroendocrine Tumors

Bhadrasain Vikram, MD – Complementary Role of Radionuclide Therapy in Radiation Oncology  


Day 2 Break-out Summaries and Highlights:

Fred Fahey, DSc – Opening Remarks

Janis O’Malley – Summary Report, Break-out Group 1: Lymphoma

David I. Quinn, PhD – Summary Report, Break-out Group 2: Bone Therapy  

Wolfgang Weber, MD – Summary Report, Break-out Group 3: Solid Tumors

Anath Srinivasan, PhD – Summary Report, Break-out Group 4: Neuroendocrine

Hossein Jadvar, MD, PhD - Highlights and Future Direction